David Schamp, MD, is Chief of Electrophysiology at MedStar Union Memorial Hospital, a cardiologist at MedStar Franklin Square Medical Center, and has a clinical practice at MedStar Chesapeake CardioVascular Associates in Baltimore.
He specializes in complex heart rhythm management, participating in cutting-edge trials as well as device implantation. Dr. Schamp is board-certified in Internal Medicine, Cardiovascular Disease, and Clinical Cardiac Electrophysiology. He is a member of the Heart Rhythm Society.
He received his medical degree from the University of Maryland School of Medicine and completed an internship and residency in Internal Medicine at the University of Maryland Hospital in Baltimore. He continued his training with a fellowship in Cardiovascular Disease at the University of Maryland and a fellowship in Clinical Cardiac Electrophysiology at the Cardiovascular Research Institute of the University of California in San Francisco.
Dr. Schamp's research interests include
- Cardiovascular disease
- Cardiac electrophysiology
- Catheter ablation
- Cardiac drug trials
- Cardiac resynchronization
A Study of SCH 530348 in Addition to Standard Care in Patients with Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP - TIMI 50)
Dr, Schamp was a principal investigator on this study, sponsored by Schering Plough. This study was designed to determine whether the addition of SCH 530348 to standard care would help prevent heart attacks and stroke in patients with a history of atherosclerosis. This study also assessed risk of bleeding with this drug.
Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation (ARISTOTLE)
Dr. Schamp was a sub-investigator on this study, sponsored by Bristol-Myers Squibb. In this Phase 3 trial of patients with atrial fibrillation, apixaban was found to be superior to warfarin in preventing stroke.
- Research Areas